MedTrace Logo

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

NCT02436759 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-10-28

Study results available
· View outcomes & findings →

Summary

This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.

Conditions

  • Acquired Blepharoptosis

Interventions

DRUG

RVL-1201

RVL-1201 Ophthalmic Solution 0.1%

DRUG

RVL-1201 Vehicle Placebo

RVL-1201 Vehicle Placebo

Sponsors & Collaborators

  • RVL Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Chuck Slonim, MD · Oculos Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02436759 on ClinicalTrials.gov